Immunicum is a biopharmaceutical company that develops immune therapies against a range of various tumors. The Company's lead product, ilixadencel, has been developed to be able to take advantage of each patient's own tumor antigen. Immunicum is also engaged in research and development for production of pharmaceuticals.
|Employees (est.) (Feb 2019)||11||(-15%)|
|Share Price (May 2020)||KR9.7||(-2%)|
Market capitalization (27-Apr-2020)
Closing stock price (27-Apr-2020)
Immunicum has 505 Twitter Followers. The number of followers has increased 0.7% month over month and increased 2.9% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
When was Immunicum founded?
Immunicum was founded in 2002.
Who are Immunicum key executives?
Immunicum's key executives are Michael Oredsson, Michaela Gertz and Alex Karlsson-Parra.
How many employees does Immunicum have?
Immunicum has 11 employees.
Who are Immunicum competitors?
Competitors of Immunicum include Retrophin, Palatin Technologies and GBT (Global Blood Therapeutics).
Where is Immunicum headquarters?
Immunicum headquarters is located at Östermalmstorg 5, Stockholm.
Where are Immunicum offices?
Immunicum has an office in Stockholm.
How many offices does Immunicum have?
Immunicum has 1 office.
Receive alerts for 300+ data fields across thousands of companies